Related references
Note: Only part of the references are listed.Lupus-Like Syndrome Attributable to Anti—Tumor Necrosis Factor α Therapy in 14 Patients During an 8-Year Period at Mayo Clinic
David A. Wetter et al.
MAYO CLINIC PROCEEDINGS (2012)
Progressive Multifocal Leukoencephalopathy in Patients on Immunomodulatory Therapies
Eugene O. Major
ANNUAL REVIEW OF MEDICINE (2010)
Investigational Immunotherapeutics for B-Cell Malignancies
Alfonso Quintas-Cardama et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
An Interspecies Comparison of Placental Antibody Transfer: New Insights Into Developmental Toxicity Testing of Monoclonal Antibodies
Nele Pentsuk et al.
BIRTH DEFECTS RESEARCH PART B-DEVELOPMENTAL AND REPRODUCTIVE TOXICOLOGY (2009)
Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclasses
Pierre Bruhns et al.
BLOOD (2009)
The state of the art: immune-mediated mechanisms of monoclonal antibodies in cancer therapy
J. Griggs et al.
BRITISH JOURNAL OF CANCER (2009)
Use of pharmacokinetic/pharmacodynamic modelling for starting dose selection in first-in-human trials of high-risk biologics
Balaji M. Agoram
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2009)
The Trifunctional Antibody Ertumaxomab Destroys Tumor Cells That Express Low Levels of Human Epidermal Growth Factor Receptor 2
Michael Jaeger et al.
CANCER RESEARCH (2009)
Safety Assessment and Dose Selection for First-in-Human Clinical Trials With Immunomodulatory Monoclonal Antibodies
P. Y. Muller et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Integrated studies of biology: multiplexed imaging assays from molecules to man and back
Kevin W. Eliceiri et al.
CURRENT OPINION IN BIOTECHNOLOGY (2009)
Novel targeted therapies for autoimmunity
E. William St Clair
CURRENT OPINION IN IMMUNOLOGY (2009)
Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor-α antagonists
John D. Isaacs
EXPERT OPINION ON BIOLOGICAL THERAPY (2009)
Evaluation of the Immuno-Stimulatory Potential of Stopper Extractables and Leachables by Using Dendritic Cells as Readout
Robert Mueller et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2009)
Preclinical development of monoclonal antibodies Considerations for the use of non-human primates
Kathryn Chapman et al.
MABS (2009)
Immunotoxicity of monoclonal antibodies
Jacques Descotes
MABS (2009)
Practical considerations for nonclinical safety evaluation of therapeutic monoclonal antibodies
Carmel M. Lynch et al.
MABS (2009)
Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo
Aran F. Labrijn et al.
NATURE BIOTECHNOLOGY (2009)
Progressive Multifocal Leukoencephalopathy after Natalizumab Monotherapy
Hans Linda et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Risk of High-Grade Skin Rash in Cancer Patients Treated with Cetuximab - an Antibody against Epidermal Growth Factor Receptor: Systemic Review and Meta-Analysis
Xiao Su et al.
ONCOLOGY (2009)
Developmental toxicity testing of monoclonal antibodies: An enhanced pre- and postnatal study design option
Jane Stewart
REPRODUCTIVE TOXICOLOGY (2009)
Toll-like receptors (TLRs) and Nod-like receptors (NLRs) in inflammatory disorders
Masayuki Fukata et al.
SEMINARS IN IMMUNOLOGY (2009)
Structural characterization of a human Fc fragment engineered for lack of effector functions
Vaheh Oganesyan et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2008)
NK cell tolerance and the maternal-fetal interface
Joan K. Riley et al.
AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY (2008)
Trastuzumab cardiotoxicity: biological hypotheses and clinical open issues
Emilio Bria et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2008)
Recombinant antibodies for cancer therapy
Mahendra P. Deonarain
EXPERT OPINION ON BIOLOGICAL THERAPY (2008)
Clinical immunotoxicity of therapeutic proteins
Jacques Descotes et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2008)
What's so special about the developing immune system?
Leigh Ann Burns-Naas et al.
INTERNATIONAL JOURNAL OF TOXICOLOGY (2008)
Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products
Eugen Koren et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2008)
Developmental immunotoxicology (DIT): windows of vulnerability, immune dysfunction and safety assessment
Rodney R. Dietert
JOURNAL OF IMMUNOTOXICOLOGY (2008)
Testing human biological in animal host resistance models
Gary R. Burleson et al.
JOURNAL OF IMMUNOTOXICOLOGY (2008)
Adverse consequences of immunostimulation
Rafael Ponce
JOURNAL OF IMMUNOTOXICOLOGY (2008)
Monoclonal antibody first dose cytokine wease syndromes-mechanisms and prediction
Mark Wing
JOURNAL OF IMMUNOTOXICOLOGY (2008)
Monoclonal antibodies in the therapy of multiple sclerosis An overview
P. S. Rommer et al.
JOURNAL OF NEUROLOGY (2008)
Cetuximab-induced anaphylaxis and IgE specific for galactose-α-1,3-galactose
Christine H. Chung et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
New Approaches to Prediction of Immune Responses to Therapeutic Proteins during Preclinical Development
Laura C. A. Perry et al.
DRUGS IN R&D (2008)
Fc gamma receptors as regulators of immune responses
Falk Nimmerjahn et al.
NATURE REVIEWS IMMUNOLOGY (2008)
Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis
James C. Yang et al.
JOURNAL OF IMMUNOTHERAPY (2007)
The role of the CTLA4 blockade in the treatment of malignant melanoma
Lee D. Cranmer et al.
CANCER INVESTIGATION (2007)
On the anticipation of the human dose in first-in-man trials from preclinical and prior clinical information in early drug development
P. J. Lowe et al.
XENOBIOTICA (2007)
Cytokine Storm in the phase I trial of monoclonal antibody TGN1412: Better understanding the causes to improve preclinical testing of immunotherapeutics
Richard Stebbings et al.
JOURNAL OF IMMUNOLOGY (2007)
Eculizumab: A novel therapy for paroxysmal nocturnal hemoglobinuria
Karolina M. Zareba
DRUGS OF TODAY (2007)
Effects of an anti-TNF-α monoclonal antibody, administered throughout pregnancy and lactation, on the development of the macaque immune system
Pauline L. Martin et al.
AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY (2007)
Immunotoxicity evaluation by immune fucntion tests: Focus on the T-dependent antibody response(TDAR) [overview of a workshop session at the 45th annual meeting of the society of toxicology (SOT) March 5-9, 2006 San Diego, CA]
Danuta J. Herzyk et al.
JOURNAL OF IMMUNOTOXICOLOGY (2007)
Immunostimulatory monoclonal antibodies for cancer therapy
Ignacio Melero et al.
NATURE REVIEWS CANCER (2007)
Influenza virus host resistance model
Gary R. Burleson et al.
METHODS (2007)
Antigen-presenting cells and materno-fetal tolerance: An emerging role for dendritic cells
Gordana Laskarin et al.
AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY (2007)
Bacterial host resistance models in the evaluation of immunotoxicity
Mitchell D. Cohen
METHODS (2007)
Antibody therapeutics: isotype and glycoform selection
Roy Jefferis
EXPERT OPINION ON BIOLOGICAL THERAPY (2007)
FcRn: the neonatal Fc receptor comes of age
Derry C. Roopenian et al.
NATURE REVIEWS IMMUNOLOGY (2007)
Natalizumab and progressive multifocal leucoencephalopathy
J. R. Berger
ANNALS OF THE RHEUMATIC DISEASES (2006)
IgG fc receptor III homologues in nonhuman primate species: Genetic characterization and ligand interactions
Kenneth A. Rogers et al.
JOURNAL OF IMMUNOLOGY (2006)
Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412
Ganesh Suntharalingam et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Loss of Siglec expression on T lymphocytes during human evolution
Dzung H. Nguyen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Immune surveillance in multiple sclerosis patients treated with natalizumab
O Stüve et al.
ANNALS OF NEUROLOGY (2006)
B-Cell-targeted therapy for systemic lupus erythematosus
Ramin Sabahi et al.
DRUGS (2006)
Structural characterization and immunogenicity in wild-type and immune tolerant mice of degraded recombinant human interferon alpha2b
S Hermeling et al.
PHARMACEUTICAL RESEARCH (2005)
Tolerability and safety of rituximab (MabThera®)
E Kimby
CANCER TREATMENT REVIEWS (2005)
Siglecs in innate immunity
PR Crocker
CURRENT OPINION IN PHARMACOLOGY (2005)
Biologic therapies in clinical development for the treatment of rheumatoid arthritis
MC Genovese
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY (2005)
Generating quantitative models describing the sequence specificity of biological processes with the stabilized matrix method
B Peters et al.
BMC BIOINFORMATICS (2005)
Triggering of OX40 (CD134) on CD4+CD25+ T cells blocks their inhibitory activity:: a novel regulatory role for OX40 and its comparison with GITR
B Valzasina et al.
BLOOD (2005)
STP position paper: Best practice guideline for the routine pathology evaluation of the immune system
P Haley et al.
TOXICOLOGIC PATHOLOGY (2005)
Anchor profiles of HLA-specific peptides: Analysis by a novel affinity scoring method and experimental validation
J Desmet et al.
PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS (2005)
Infections associated with tumor necrosis factor-alpha antagonists
DJ Rychly et al.
PHARMACOTHERAPY (2005)
Development of a human adaptive immune system in cord blood cell-transplanted mice
E Traggiai et al.
SCIENCE (2004)
The accuracy of extended histopathology to detect immunotoxic chemicals
DR Germolec et al.
TOXICOLOGICAL SCIENCES (2004)
Evaluation of a surrogate antibody for preclinical safety testing of an anti-CD11a monoclonal antibody
J Clarke et al.
REGULATORY TOXICOLOGY AND PHARMACOLOGY (2004)
The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation
SI Fujii et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
Improved prediction of MHC class I and class II epitopes using a novel Gibbs sampling approach
M Nielsen et al.
BIOINFORMATICS (2004)
Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed
BA van de Putte et al.
ANNALS OF THE RHEUMATIC DISEASES (2004)
Species differences in the structure and function of the immune system
PJ Haley
TOXICOLOGY (2003)
Adalimumab, a fully human anti-tumor necrosis factor a monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate - The ARMADA trial
ME Weinblatt et al.
ARTHRITIS AND RHEUMATISM (2003)
NOD/SCID/γcnull mouse:: an excellent recipient mouse model for engraftment of human cells
M Ito et al.
BLOOD (2002)
Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin.
N Casadevall et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Antigen-antibody immune complexes empower dendritic cells to efficiently prime specific CD8(+) CTL responses in vivo
DH Schuurhuis et al.
JOURNAL OF IMMUNOLOGY (2002)
Thrombocytopenia caused by the development of antibodies to thrombopoietin
JZ Li et al.
BLOOD (2001)
Whole blood cytokine response as a measure of immunotoxicity
I Langezaal et al.
TOXICOLOGY IN VITRO (2001)
Preclinical development of keliximab, a Primatized™ anti-CD4 monoclonal antibody, in human CD4 transgenic mice:: characterization of the model and safety studies
PJ Bugelski et al.
HUMAN & EXPERIMENTAL TOXICOLOGY (2000)
Using an analogous monoclonal antibody to evaluate the reproductive and chronic toxicity potential for a humanized anti-TNFα monoclonal antibody
G Treacy
HUMAN & EXPERIMENTAL TOXICOLOGY (2000)
Histopathologic approaches to detect changes indicative of immunotoxicity
CF Kuper et al.
TOXICOLOGIC PATHOLOGY (2000)
Share Paper
